Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence

Pseudoprogression Following Chemoradiotherapy for Glioblastoma Multiforme

(2014) Paul Sanghera et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prediction of Pseudoprogression in Patients with Glioblastomas Using the Initial and Final Area Under the Curves Ratio Derived from Dynamic Contrast-Enhanced T1-Weighted Perfusion MR Imaging

(2013) C.H. Suh et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?

(2013) Ashish H. Shah et al.   JOURNAL OF NEURO-ONCOLOGY

Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies

(2013) Nishant Verma et al.   NEURO-ONCOLOGY

Diffusion-weighted MR Imaging for the Differentiation of True Progression from Pseudoprogression Following Concomitant Radiotherapy with Temozolomide in Patients with Newly Diagnosed High-grade Gliomas

(2012) Woong Jae Lee et al.   ACADEMIC RADIOLOGY

Late and Prolonged Pseudoprogression in Glioblastoma After Treatment With Lomustine and Temozolomide

(2012) Moritz Stuplich et al.   JOURNAL OF CLINICAL ONCOLOGY

Response Assessment in Neuro-Oncology Criteria: Implementation Challenges in Multicenter Neuro-Oncology Trials

(2011) W.B. Pope et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma

(2011) L.C. Hygino da Cruz et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Pseudoprogression: Relevance With Respect to Treatment of High-Grade Gliomas

(2011) James Fink et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Potential for Differentiation of Pseudoprogression From True Tumor Progression With Dynamic Susceptibility-Weighted Contrast-Enhanced Magnetic Resonance Imaging Using Ferumoxytol vs. Gadoteridol: A Pilot Study

(2010) Seymur Gahramanov et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Changes in Relative Cerebral Blood Volume 1 Month after Radiation-Temozolomide Therapy Can Help Predict Overall Survival in Patients with Glioblastoma

(2010) Rajiv Mangla et al.   RADIOLOGY

MR Spectroscopy in Radiation Injury

(2009) P.C. Sundgren   AMERICAN JOURNAL OF NEURORADIOLOGY

Pseudoprogression and pseudoresponse in the treatment of gliomas

(2009) Dieta Brandsma et al.   CURRENT OPINION IN NEUROLOGY

Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation WithMGMTPromoter Methylation Status

(2009) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression

(2009) Elizabeth R. Gerstner et al.   JOURNAL OF NEURO-ONCOLOGY

Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations

(2009) Cristo Chaskis et al.   SURGICAL NEUROLOGY

Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

(2008) Walter Taal et al.   CANCER

MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

(2008) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

(2008) Dieta Brandsma et al.   LANCET ONCOLOGY

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE